Overview

Dimenydrinate vs Ondansetron for PONV (DONV)

Status:
Recruiting

Trial end date:
2022-11-30

Target enrollment:

Participant gender:

Summary

This study will investigate the impact of dimenydrinate (H1-receptor antagonist) versus ondansetron (HT3-receptor antagonist) in postoperative nausea and vomiting, in surgery-related preoperative stress and in the incidence of postoperative complications that could lengthen the LOS in PACU and/or the overall LOS.

Phase:

N/A

Details

Lead Sponsor:

University of Thessaly

Treatments:

Dimenhydrinate
Ondansetron